Signals, Powered By EquityPandit
Glenmark Pharmaceuticals has entered into an agreement with Cyndea Pharma to develop generic soft-gelatin capsule formulations of certain pharmaceutical products.
Glenmark Pharmaceuticals has said in a BSE filing that “it has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S L, granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products.”
Glenmark, under this agreement, receives exclusive rights to the US and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales.
